VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines

Details VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines

2006-09-22

2009-11-10

Morris, Patricia L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S309000, C546S141000, C546S142000, C546S143000

Reexamination Certificate

active

07615565

ABSTRACT:
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.

REFERENCES:
patent: 3226394 (1965-12-01), Schippet et al.
patent: 4568687 (1986-02-01), Wright et al.
patent: 5716993 (1998-02-01), Ozaki et al.
patent: 6448277 (2002-09-01), Altmann et al.
patent: 6548548 (2003-04-01), Campbell et al.
patent: 6818661 (2004-11-01), Seidelmann et al.
patent: 6878720 (2005-04-01), Altmann et al.
patent: 7002022 (2006-02-01), Altmann et al.
patent: 7122547 (2006-10-01), Huth et al.
patent: 7148357 (2006-12-01), Huth et al.
patent: 7202260 (2007-04-01), Huth et al.
patent: 7307088 (2007-12-01), Huang et al.
patent: 7429592 (2008-09-01), Ernst et al.
patent: 2002/0019414 (2002-02-01), Altmann et al.
patent: 2002/0147198 (2002-10-01), Chen et al.
patent: 2003/0134836 (2003-07-01), Elbaum et al.
patent: 2003/0176469 (2003-09-01), Seidelmann et al.
patent: 2003/0225106 (2003-12-01), Askew et al.
patent: 2004/0029880 (2004-02-01), Krueger et al.
patent: 2004/0039019 (2004-02-01), Huth et al.
patent: 2004/0102441 (2004-05-01), Krueger et al.
patent: 2004/0254185 (2004-12-01), Ernst et al.
patent: 2004/0266770 (2004-12-01), Ernst et al.
patent: 2005/0032816 (2005-02-01), Ernst et al.
patent: 2005/0054654 (2005-03-01), Huth et al.
patent: 2005/0261343 (2005-11-01), Krueger et al.
patent: 2006/0116380 (2006-06-01), Bohlmann et al.
patent: 2006/0160861 (2006-07-01), Bohlmann et al.
patent: 2006/0264425 (2006-11-01), Bohlmann et al.
patent: 2007/0015794 (2007-01-01), Huth et al.
patent: 2007/0135489 (2007-06-01), Huth et al.
patent: 2652144 (1978-05-01), None
patent: 3406416 (1984-08-01), None
patent: 19910396 (2000-09-01), None
patent: 10023486 (2002-03-01), None
patent: 10228090 (2004-01-01), None
patent: 0564356 (1993-10-01), None
patent: 0650961 (1995-05-01), None
patent: 06/86625 (1995-12-01), None
patent: 50157383 (1975-12-01), None
patent: WO 9426260 (1994-11-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 00/27819 (2000-05-01), None
patent: WO 00/27820 (2000-05-01), None
patent: WO 00/39118 (2000-07-01), None
patent: WO 01/55114 (2001-08-01), None
patent: 01 85691 (2001-11-01), None
patent: WO 01/85715 (2001-11-01), None
patent: 02 055501 (2002-07-01), None
patent: 02 066470 (2002-08-01), None
patent: 02 905352 (2002-11-01), None
patent: WO 02/090352 (2002-11-01), None
patent: WO 03/040102 (2003-05-01), None
patent: 03 048158 (2003-06-01), None
patent: WO 2004/013102 (2004-02-01), None
J. Med. Chem. 2002, 45, 5687-5693; Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibiotrs; Paul W. Manley et al.
Augustin et al.: “Antiangiogenic Tumour Therapy: Will It Work?” Elsevier Trends Journal, vol. 19, No. 6, Jun. 1, 1998, pp. 216-222, XP004145666.
Strandtmann et al., J. Med. Chem. vol. 10, No. 6, 1967, pp. 1063-1065.
Sofina et al.: “Experimental Evaluation of Anti-Tumor Drugs in the USA and USSR and Clincal Correltaions,” NCI Monograph 55, NIH Publication No. 80/1933 (1980).
Wermuth et al.: “The Practice of Medicinal Chemistry” Practice of Medicninal Chemistry XX, XX, 1996 pp. 203-237, XP002190259.
Montginoul et al.: “Analgesic, Anticonvulsant and Anti-Inflammatory Activities of 1H, 3H-Quinazoline-2,4-Diones” Chemical Abstracts Service, Coloumbus, Ohio, US; Retreived From STN Database Accession No. 110:165551H; XP002135868; Ann. Pharm. FR (1989) vol. 46, No. 4, pp. 223-332.
Noda et al.: “Quinazoline Compounds” Chemical Abstracts, Jul. 19, 1976, vol. 85, No. 3, XP002135867.
Hardtmann et al.: “Chemistry of 2H-3,1-Benzoxazine-2,4 (1H)-Dione (Isatoic Anhydrides). I. Sythesis of N-Substitutded2H-3,1-Benzoxazine-2,4(1H)-Dione” Journal of Heterocyclic Chemistry, 1975,vol. 12, No. 3, pp. 565-572, Heterocorporation, XP002135866.
Pastor et al.: “Synthesis of New 1H,3H-Quinazoline-2,4-Diones”, Bulletin De La Societe Chimique DE France, vol. 5-6, No. 2, 1975, pp. 1331-1338, XP002135865.
Golub et al. “Science” 1999, vol. 286, p. 521-537.
Lala et al.: “Cancer and Metastasis Reviews” 1998, vol. 17, No. 1, p. 91-106.
“Cancer” Retrieved Via Internet Jan. 10, 2008, URL:http://www.nlm.nih.gov/medlineplus/cancer.html.
“Tautomer” Retrieced Via Internet Jan. 10, 2008, URL:http://en.wikipedia.org/wiki/tautomer.
“Isomer” Retrieved Via Internet Jan. 10, 2008, URL:http://en.wikipedia.org/wiki/lsomer.
Verweij et al.: “Multi-Tatget Tyrosine Kinase Inhibition: and the Winner Is . . . ”, Journal of Clinical Oncology, vol. 25, No. 17, Jun. 10, 2007.
Hanrahan et al.: “Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD217 in Lung Cancer”, Cliical Cancer Search 2007; vol. 13 (15 Suppl) Aug. 1, 2007.
U.S. Appl. No. 10/631,018.
U.S. Appl. No. 11/525,091.
English Abstracts of Hardtmann et al.: “Chemistry of 2H-3,1-Benzoxazine-2,4 (1H)-Dione (Isatoic Anhydrides). I. Sythesis of N-Substituted2H-3,1-Benzoxazine-2,4(1H)-Dione” Journal of Heterocyclic Chemistry, 1975,vol. 12, No. 3, pp. 565-572, Heterocorporation, XP002135866.
English Abstracts of Pastor et al.: “Synthesis of New 1H,3H-QUINAZOLINE-2,4-Diones”, Bulletin De La Societe Chimique De France, vol. 5-6, No. 2, 1975, pp. 1331-1338, XP002135865.
Non Final Rejection Dated Dec. 5, 2008—U.S. Appl. No. 11/262,953 Filed Nov. 1, 2005 (Publication No. 2006/0160861 A1).
Final Rejection Dated Dec. 17, 2008—U.S. Appl. No. 11/525,091 Filed Sep. 22, 2006 (Publication No. 2007/0015794 A1).
Non Final Rejection Dated Mar. 17, 2008—U.S. Appl. No. 11/525,091 Filed Sep. 22, 2006 (Publication No. 2007/0015794 A1).
Non Final Rejection Dated Oct. 8, 2008—U.S. Appl. No. 11/265,516 Filed Nov. 3, 2005 (Publication No. 2006/0264426 A1).
Non Final Rejection Dated Dec. 6, 2005—U.S. Appl. No. 10/631,018 Filed Jul. 31, 2003 (Publication No. 2004/0147535 A1).
Non Final Rejection Dated Nov. 24, 2004—U.S. Appl. No. 10/275,479 Filed Jun. 23, 2003 (Publication No. 2004/00298880 A1).
Final Rejection Dated May 3, 2005—U.S. Appl. No. 10/275,480 Filed Jun. 24, 2003 (Publication No. 2004/0102441 A1).
Non Final Rejection Dated Nov. 19, 2004—U.S. Appl. No. 10/275,480 Filed Jun. 24, 2003 (Publication No. 2004/0102441 A1).
Non Final Rejection Dated Mar. 3, 2004—U.S. Appl. No. 10/275,480 Filed Jun. 24, 2003 (Publication No. 2004/0102441 A1).
Non Final Rejection Dated Apr. 2, 2007—U.S. Appl. No. 10/476,761 Filed Aug. 25, 2004 (Publication No. 2004/0266770 A1).
Non Final Rejection Dated Feb. 21, 2002—U.S. Appl. No. 09/831,506 Filed Sep. 14, 2001.
Non Final Rejection Dated Jun. 12, 2002—U.S. Appl. No. 09/831,506 Filed Sep. 14, 2001.
Final Rejection Dated Dec. 30, 2002&#

Affiliated with

Also associated with

Rating

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4097985